Recent developments in the treatment of bipolar disorders

Bibliography

• KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry(1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• The Global Burden of Disease. CL Murray, AD Lopez (Eds), Harvard University Press (1996).
   Google Scholar
• PESELOW ED, SOLOWAY S: Ten-year outcome in patients with bipolar disorder. 2003 American Psychological Association Annual Meeting, San Francisco, CA, USA (2003).
   Google Scholar
• TOHEN M, WATERNAUX CM, TSUANG MT: Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch. Gen. Psychiatry (1990) 47:1106–1111.
   Google Scholar
• KECK PE Jr, MCELROY SL, STRAKOWSKI SM et al.: 12-Month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am. J. Psychiatry(1998) 155:646–652.
   PubMed Web of Science ®Google Scholar
• YEREVANIAN BI, KOEK RJ, MINTZ J:Lithium, anticonvulsants and suicidal behavior in bipolar disorder. Affect. Disord. (2003) 73:223–228.
   PubMed Web of Science ®Google Scholar
• SCHATZBERG AF, NEMEROFF CB: Textbook of Psychopharmacology American Psychiatric Press (1998).
   Google Scholar
• BROWN ES, NEJTEK VA, PERANTIE DC, ORSULAK PJ, BOBADILLA L: Lamotrigine in patients with bipolar disorder and cocaine dependence. j. Clin. Psychiatry (2003) 64:197–201.
   PubMed Web of Science ®Google Scholar
• PERUGI G, TONI C, FRARE F et al.: Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? Clin. Psychopharmacol. (2002) 22:584–591.
   Web of Science ®Google Scholar
• CARTA MG, HARDOY MC, HARDOY MJ, GRUNZE H, CARPINIELLO B: The clinical use of gabapentin in bipolar spectrum disorders. Affect. Disord. (2003) 75:83–91.
   PubMed Web of Science ®Google Scholar
• SALLOUM IM, CORNELIUS JR, CHAKRAVORTHY S: Combined naltrexone valproate in bipolar alcoholics: a randomized, open-label, pilot study. Bipolar Disord. (2003) 5:79.
   PubMedGoogle Scholar
• SALLOUM IM, CORNELIUS JR, DALEY DC et al.: Efficacy of valproate in bipolar alcoholics: a double blind, placebo-controlled study. Bipolar Disord. (2003) 5:80.
   PubMedGoogle Scholar
• KECK PE Jr, MCELROY SL: Redefiningmood stabilization. J. Affect. Disord. (2003) 73:163–169.
   PubMedGoogle Scholar
• CADE JFJ: Lithium salts in the treatment of psychotic excitement. Med. J. Aust. (1949) 2:349–352.
   PubMed Web of Science ®Google Scholar
• MONDIMORE FM, FULLER GA, DEPAULO JR: Drug combinations for mania. I Clin. Psychiatry (2003) 64\(Suppl. 5):25–31.
   Google Scholar
• GOODWIN FK: Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J. Clin. Psychiatry (2003) 64\(Suppl. 5):18–24.
   Google Scholar
• GROF P: Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J. Gin. Psychiatry(2003) 64\(Suppl. 5):53–61.
   Google Scholar
• BERRETTINI W: Shared genetic susceptibility for bipolar and schizophrenic disorders. Bipolar Disord. (2003) 5:15.
   Google Scholar
• WANG JF, BOWN CD, CHEN B, YOUNG LT: Identification of mood stabilizer-regulated genes by differential-display PCR. Int. J. Neuropsychopharmacol (2001) 4:65–74.
   PubMed Web of Science ®Google Scholar
• MANJI HK: Neuroplasticity and cellular resilience in bipolar disorder. Bipolar Disord. (2003) 5:14–15.
   PubMedGoogle Scholar
• DAVIS KA, YUCEL K, CARDENAS VA, DEICKEN RF: Frontal and anterior cingulate cortex volume reductions in familial bipolar I disorder. Biol. Psychiatry (2003) 53:91S.
   Web of Science ®Google Scholar
• HAUSER P, MATOCHIK J, ALTSHULER LL et al.: MRI-based measurements of temporal lobe and ventricular structures in patients with bipolar I and bipolar II disorders. Affect. Disord. (2000) 60:25–32.
   PubMed Web of Science ®Google Scholar
• ALTSHULER LL, CURRAN JG, HAUSER P et al.: T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am. J. Psychiatry(1995) 152:1139–1144.
   PubMed Web of Science ®Google Scholar
• ALTSHULER LL, BARTZOKIS G, GRIEDER T et al.: An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia. Biol. Psychiatry (2000) 48:147–162.
   PubMed Web of Science ®Google Scholar
• BEYER JL, KRISHNAN KR: Volumetric brain imaging findings in mood disorders. Bipolar Disord. (2002) 4:89–104.
   PubMed Web of Science ®Google Scholar
• NORRIS SD, KRISHNAN KR, AHEARN E: Structural changes in the brain of patients with bipolar affective disorder by MRI: a review of the literature. Frog. Neuropsychopharmacol Biol. Psychiatry (1997) 21:1323–1337.
   PubMed Web of Science ®Google Scholar
• KRISHNAN KR: Brain imaging correlates. J. Clin. Psychiatry(1999) 60\(Suppl. 15):50–54.
   Google Scholar
• BRAMBILLA P, HARENSKI K, NICOLETTI MA et al.: Anatomical MRI study of basal ganglia in bipolar disorder patients. Psychiatry Res. (2001) 106:65–80.
   PubMed Web of Science ®Google Scholar
• BRAMBILLA P, HARENSKI K, NICOLETTI M et al.: MRI study of posterior fossa structures and brain ventricles in bipolar patients. J. Psychiatr. Res. (2001) 35:313–322.
   PubMed Web of Science ®Google Scholar
• CAETANO SC, SASSI R, BRAMBILLA P et al.: MRI study of thalamic volumes in bipolar and unipolar patients and healthy individuals. Psychiatry Res. (2001) 108:161–168.
   PubMed Web of Science ®Google Scholar
• SASSI RB, NICOLETTI M, BRAMBILLA P et al: Decreased pituitary volume in patients with bipolar disorder. Biol. Psychiatry (2001) 50:271–280.
   PubMed Web of Science ®Google Scholar
• HAO Y, ZHANG L, MANJI HK, CHEN B: Mood-stabilizer valproate enhances cortical neuron growth/ regeneration and survival. Biol. Psychiatry (2003) 53:72S.
   Web of Science ®Google Scholar
• BRAMBILLA P, SALA M, NICOLETTI M et al.: Dorsolateral prefrontal cortex volumes in lithium treated bipolar patients. Biol. Psychiatry (2003) 53:92S.
   Web of Science ®Google Scholar
• LI X, KETTER TA, FRYE MA: Synaptic,intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? Affect. Disord. (2002) 69:1–14.
   Google Scholar
• ICHIM L, BERK M, BROOK S: Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann. Clin. Psychiatry(2000) 12:5–10.
   PubMedGoogle Scholar
• BERK M: Lamotrigine and the treatment of mania in bipolar disorder. Eur: Neuropsychopharmacol (1999) 9\(Suppl. 4):S119–S123.
   Google Scholar
• FRYE MA, KETTER TA, KIMBRELL TA et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol (2000) 20:607–614.
   PubMed Web of Science ®Google Scholar
• WALDEN J, SCHAERER L, SCHLOESSER S, GRUNZE H: An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord. (2000) 2:336–339.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, SUPPES T, BOWDEN CL et al.: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. Clin. Psychiatry (2000) 61:841–850.
   Google Scholar
• CALABRESE JR, BOWDEN CL, SACHS GS et al.: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Clin. Psychiatry(1999) 60:79–88.
   Google Scholar
• •This is an important clinical trial that demonstrates the efficacy of lamotrigine in bipolar depression.
   Google Scholar
• BOWDEN CL, CALABRESE JR, SACHS G et al: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry (2003) 60:392–400.
   PubMed Web of Science ®Google Scholar
• •This is an important clinical trial that demonstrates the efficacy of lamotrigine in maintenance therapy for bipolar disorder.
   Google Scholar
• CALABRESE JR, BOWDEN CL, MEE-LEE D et al.: Lamotrigine or lithium in the maintenance treatment of bipolar I disorder. American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, USA (2002).
   Google Scholar
• NORMANN C, LANGOSCH J, SCHAERER LO, GRUNZE H, WALDEN J: Treatment of acute mania with topiramate. Am. J. Psychiatry (1999) 156:2014.
   PubMed Web of Science ®Google Scholar
• MARCOTTE D: Use of topiramate, a newanti-epileptic as a mood stabilizer. Affect. Disord. (1998) 50:245–251.
   PubMed Web of Science ®Google Scholar
• MCELROY SL, SUPPES T, KECK PE et al.: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatry (2000) 47:1025–1033.
   PubMed Web of Science ®Google Scholar
• GRUNZE HC, NORMANN C, LANGOSCH J et al: Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. j Clin. Psychiatry (2001) 62:464–468.
   PubMed Web of Science ®Google Scholar
• VIETA E, TORRENT C, GARCIA-RIBAS G et al: Use of topiramate in treatment-resistant bipolar spectrum disorders. Clin. Psychopharmacol (2002) 22:431–435.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, MANCINI DA, MCCANN S et al.: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. (2002) 4:207–213.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, KUSUMAKAR V, CALABRESE JR et al.: Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. I Clin. Psychiatry(2002) 63:275–283.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR: Topiramate versus placebo in mania. American Psychiatric Association Annual Meeting, Chicago, IL, USA (2000).
   Google Scholar
• JOHNSON BA, AIT-DAOUD N, BOWDEN CL et al.: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 361:1677–1685.
   PubMed Web of Science ®Google Scholar
• SCHAFFER CB, SCHAFFER LC: Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. Affect. Disord. (1999) 55:237–240.
   PubMed Web of Science ®Google Scholar
• PERUGI G, TONI C, RUFFOLO G et al:Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiamy (1999) 32:136–141.
   PubMed Web of Science ®Google Scholar
• ERFURTH A, KAMMERER C, GRUNZE H, NORMANN C, WALDEN J: An open label study of gabapentin in the treatment of acute mania. Psychiatr. Res. (1998) 32:261–264.
   Google Scholar
• MCELROY SL, SOUTULLO CA, KECK PE Jr, KMETZ GF: A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann. Clin. Psychiatry (1997) 9:99–103.
   PubMedGoogle Scholar
• GHAEMI SN, KATZOW JJ, DESAI SP, GOODWIN FK: Gabapentin treatment of mood disorders: a preliminary study. Clin. Psychiatry (1998) 59:426–429.
   PubMed Web of Science ®Google Scholar
• KNOLL J, STEGMAN K, SUPPES T: Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. I Affect. Disord (1998) 49:229–233.
   PubMed Web of Science ®Google Scholar
• SOKOLSKI KN, GREEN C, MARIS DE, DEMET EM: Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann. Clin. Psychiatry (1999) 11:217–222.
   PubMedGoogle Scholar
• YOUNG LT, ROBB JC, HASEY GM et al: Gabapentin as an adjunctive treatment in bipolar disorder. J. Affect. Disord. (1999) 55:73–77.
   PubMed Web of Science ®Google Scholar
• WANG PW, SANTOSA C, SCHUMACHER M et al.: Gabapentin augmentation therapy in bipolar depression. Bipolar Disord. (2002) 4:296–301.
   PubMed Web of Science ®Google Scholar
• PANDE AC, CROCKATT JG, JANNEY CA, WERTH JL, TSAROUCHA G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. (2000) 2:249–255.
   PubMed Web of Science ®Google Scholar
• OBROCEA GV, DUNN RIVI, FRYE MA et al.: Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol. Psychiatry(2002) 51:253–260.
   PubMed Web of Science ®Google Scholar
• MISHORY A, YAROSLAVSKY Y, BERSUDSKY Y, BELMAKER RH: Phenytoin as an antimanic anticonvulsant: a controlled study. Am. J. Psychiatry(2000) 157:463–465.
   PubMed Web of Science ®Google Scholar
• APPLEBAUM J, LEVINE J, BELMAKER RH: Intravenous fosphenytoin in acute mania.' Clin. Psychiatry (2003) 64:408–409.
   PubMed Web of Science ®Google Scholar
• CENTORRINO F, ALBERT MJ, BERRY JM et al: Clinical experience with oxcarbazepine in 56 hospitalized psychiatric patients. Bipolar Disord. (2003) 5:39.
   Google Scholar
• GRUNZE H, WALDEN J: Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. .1. Affect. Disord. (2002) 72 (Suppl.):S15–S21.
   Google Scholar
• HUMMEL B, WALDEN J, STAMPFER R et al.: Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipo/ar Disord. (2002) 4:412–417.
   PubMed Web of Science ®Google Scholar
• NASSIR GHAEMI S, KO JY, KATZOW JJ: Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disord. (2002) 4:70–74.
   PubMed Web of Science ®Google Scholar
• MCELROY SL, KECK PE, STANTON SP et al.: A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry (1996) 57:142–146.
   PubMed Web of Science ®Google Scholar
• WINSBERG ME, DEGOLIA SG, STRONG CM, KETTER TA: Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. Affect. Disord. (2001) 67:207–212.
   PubMed Web of Science ®Google Scholar
• DELBELLO MP, SCHWIERS M, ROSENBERG HL, STRAKOWSKI SM: Divalproex for the treatment of aggression associated with adolescent mania. Bipolar Disord. (2003) 5:41–42.
   Google Scholar
• SACHS GS, GROSSMAN F, GHAEMI SN, OKAMOTO A, BOWDEN CL: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry(2002) 159:1146–1154.
   PubMed Web of Science ®Google Scholar
• REVICKI DA, PARAMORE LC, SOMMERVILLE KW, SWANN AC, ZAJECKA JM: Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Clin. Psychiatry (2003) 64:288–294.
   PubMed Web of Science ®Google Scholar
• SUPPES T, ANDERSON R, DENNEHY E et al.: An open add-on study of oxcarbazepine versus divalproex to treat hypomanic symptoms in patients with bipolar disorder. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• TOHEN M, BAKER RW, ALTSHULER LL et al.: Olanzapine versus divalproex in the treatment of acute mania. Am.j Psychiatry(2002) 159:1011–1017.
   PubMed Web of Science ®Google Scholar
• TOHEN M, BAKER RW, ALTSHULER LL et al.: Olanzapine versus divalproex sodium for bipolar mania. Eur: Psychiatry' Eur. Psychiatrists (2002) 17: 109.
   Google Scholar
• BOWDEN CL, CALABRESE JR, MCELROY SL et al.: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry (2000) 57:481–489.
   PubMed Web of Science ®Google Scholar
• GYULAI L, BOWDEN CL, MCELROY SL et al: Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology (2003) 28:1374–1382.
   PubMed Web of Science ®Google Scholar
• SCHAFFER LC, SCHAFFER CB: Tiagabine and the treatment of refractory bipolar disorder. Am. Psychiatry (1999) 156:2014–2015.
   PubMed Web of Science ®Google Scholar
• KAUFMAN KR: Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann. Clin. Psychiatry (1998) 10:181–184.
   PubMedGoogle Scholar
• GRUNZE H, ERFURTH A, MARCUSE A et al.: Tiagabine appears not to be efficacious in the treatment of acute mania. I Clin. Psychiatry (1999) 60:759–762.
   PubMed Web of Science ®Google Scholar
• SUPPES T, CHISHOLM KA, DHAVALE D et al.: Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. (2002) 4:283–289.
   PubMed Web of Science ®Google Scholar
• SCHAFFER LC, SCHAFFER CB, HOWE J: An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients.' Affect. Disord. (2002) 71:259–263.
   PubMed Web of Science ®Google Scholar
• CHARLES CL, STOESZ L, TOLLEFSON G: Zonisamide-induced mania. Psychosomatics (1990) 31:214–217.
   PubMed Web of Science ®Google Scholar
• KANBA S, YAGI G, KAMIJIMA K et al: The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Frog. Neuropsychopharmacol Biol. Psychiatry (1994) 18:707–715.
   PubMed Web of Science ®Google Scholar
• BERIGAN TR: Zonisamide treatment of bipolar disorder: a case report. Can. Psychiatry (2002) 47:887.
   PubMed Web of Science ®Google Scholar
• GOLDBERG JF, BURDICK KE: Levetiracetam for acute mania. Am. Psychiatry (2002) 159:148.
   PubMed Web of Science ®Google Scholar
• BRAUNIG P, KRUGER S: Levetiracetam in the treatment of rapid cycling bipolar disorder. Psychopharmacol (2003) 17:239–241.
   Web of Science ®Google Scholar
• BRAMBILLA P, BARALE F, SOARES JC:Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl) (2003) 166:315–332.
   PubMed Web of Science ®Google Scholar
• BAKER RW, GOLDBERG JF, TOHEN M et al.: The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. Bipolar Disord. (2002) 4:43–49.
   PubMed Web of Science ®Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59:62–69.
   PubMed Web of Science ®Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al.: Olanzapine cotherapy in prevention of recurrence in bipolar disorder. Eur. Psychiatryj Ear: Psychiatrists (2002) 17: 109.
   Google Scholar
• TOHEN M, SANGER TM, MCELROY SL et al.: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. Psychiatry (1999) 156:702–709.
   PubMed Web of Science ®Google Scholar
• SANGER TM, TOHEN M, VIETA E et al.: Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Affect. Disord. (2003) 73:155–161.
   PubMed Web of Science ®Google Scholar
• SANGER TM, GRUNDY SL, GIBSON PJ et al.: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. I Gin. Psychiatry (2001) 62:273–281.
   Web of Science ®Google Scholar
• CHENGAPPA KN, BAKER RW, SHAO L et al.: Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord. (2003) 5:1–5.
   PubMed Web of Science ®Google Scholar
• BAKER RW, ZARATE CA, BROWN E, SCHUH L, TOHEN M: A three-week comparison of olanzapine versus risperidone in the treatment of bipolar mania: improvement in manic and depressive symptoms and treatment adherence. American Psychiatric Association 156th Annual Meeting, San Francisco, CA, USA (2003).
   Google Scholar
• TOHEN M, VIETA E, CALABRESE JR et al.: Olanzapine/Fluoxetine combination and olanzapine in the treatment of bipolar depression. American Psychiatric Association 156th Annual Meeting, San Francisco, CA, USA (2003).
   Google Scholar
• KETTER TA, TOHEN M, VIETA E et al: Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• ROTHSCHILD AJ, BATES KS, BOEHRINGER KL, SYED A: Olanzapine response in psychotic depression. I Clin. Psychiatry (1999) 60:116–118.
   PubMed Web of Science ®Google Scholar
• TOHEN M, BOWDEN CL, CALABRESE JR et al.: Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind, placebo-controlled 12-month clinical trial. Bipolar Disord. (2003) 5:89.
   Web of Science ®Google Scholar
• TOHEN M, MARNEROS A, BOWDEN CL et al.: Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Bipolar Disord. (2003) 5:89.
   Web of Science ®Google Scholar
• •This is an important clinical trial that demonstrates the efficacy of olanzapine in maintenance therapy for bipolar disorder.
   Google Scholar
• TOHEN M, MARNEROS A, BOWDEN CL et al.: Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12 month clinical trial. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al.: Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: an 18-month study. Biol. Psychiatry (2003) 53:134S.
   Web of Science ®Google Scholar
• MEEHAN K, ZHANG F, DAVID S et al: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. I Gin. Psychopharmacol (2001) 21:389–397.
   Web of Science ®Google Scholar
• KERWIN R: Olanzapine was more effective than lorazepam at 2 hours but not at 24 hours in bipolar mania with acute agitation. Evidence-Based Mental Health (2002) 5:18.
   PubMedGoogle Scholar
• TOHEN M, ZARATE CA Jr, CENTORRINO F et al: Risperidone in the treatment of mania. I Gin. Psychiatry (1996) 57:249–253.
   Web of Science ®Google Scholar
• GHAEMI SN, SACHS GS, BALDASSANO CE TRUMAN CJ: Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can. Psychiatry (1997) 42:196–199.
   PubMed Web of Science ®Google Scholar
• COCONCEA C, DELGADO P, SHELTON M, AMAWI L, CALABRESE JR: Risperidone augmentation in rapid cycling bipolardisorder. Bipolar Disord. (2003) 5:40.
   PubMedGoogle Scholar
• GHAEMI SN, SACHS GS: Long-term risperidone treatment in bipolar disorder: 6-month follow up. mt. Clin. Psychopharmacol (1997) 12:333–338.
   PubMed Web of Science ®Google Scholar
• VIETA E, GOIKOLEA JM, CORBELLA B et al.: Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J. Clin. Psychiatry (2001) 62:818–825.
   PubMed Web of Science ®Google Scholar
• VIETA E, GASTO C, COLOM F et al: Role of risperidone in bipolar II: an open 6-month study. J. Affect. Disord. (2001) 67:213–219.
   PubMed Web of Science ®Google Scholar
• SEGAL J, BERK M, BROOK S: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. Neuropharmacol (1998) 21:176–180.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. I Psychiatry (2003) 182:141–147.
   PubMed Web of Science ®Google Scholar
• SCHALLER JL, BEHAR D: Quetiapine for refractory mania in a child. J. Am. Acad. Child Adolesc. Psychiatry(1999) 38:498–499.
   PubMed Web of Science ®Google Scholar
• GHAEMI SN, KATZOW JJ: The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann. Clin. Psychiatry (1999) 11:137–140.
   PubMedGoogle Scholar
• ZARATE CA Jr, ROTHSCHILD A, FLETCHER KE, MADRID A, ZAPATEL J: Clinical predictors of acute response with quetiapine in psychotic mood disorders. Clin. Psychiatry (2000) 61:185–189.
   PubMed Web of Science ®Google Scholar
• BRECHER M, HUIZAR K: Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1). Bipolar Disord. (2003) 5:35–36.
   Google Scholar
• JONES M, HUIZAR K: Quetiapine as monotherapy for mania associated with bipolar disorder. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• JONES M, HUIZAR K: Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2). Bipolar Disord. (2003) 5:57.
   Google Scholar
• MULLEN J, PAULSSON B: Quetiapine in combination with mood stabilizers for the treatment of acute mania associated with bipolar disorder. Bipolar Disord. (2003) 5:70.
   Google Scholar
• MULLEN J, DEVINE N, SWEITZER D: Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM). Bipolar Disord. (2003) 5:70.
   Google Scholar
• MULLEN J, DEVINE N, SWEITZER D: Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM). 431r1 Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• KECK PE Jr, VERSIANI M, POTKIN S et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry (2003) 160:741–748.
   PubMed Web of Science ®Google Scholar
• CIAPPARELLI A, DELL'OSSO L, BANDETTINI DI POGGIO A et al: Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. j Clin. Psychiatry (2003) 64:451–458.
   PubMed Web of Science ®Google Scholar
• ZARATE CA, PAYNE JL, QUIROZ JA et al.: A double-blind study examining the efficacy of clozapine in treatment-resistant mania and mixed states. Biol. Psychiatry (2003) 53:37S.
   Web of Science ®Google Scholar
• JODY D, MARCUS R, KECK PE et al.: Aripiprazole versus placebo in acute mania. Int. J. Neuropsychopharmacol (2002) 5:S57.
   Google Scholar
• GHAEMI SN, LENOX MS, BALDESSARINI RJ: Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. I. Clin. Psychiatry (2001) 62:565–569.
   PubMed Web of Science ®Google Scholar
• KUSUMAKAR V: Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J. Clin. Psychiatry (2002) 63\(Suppl. 10):23–28.
   Google Scholar
• BALDASSANO CE GOLDBERG JF, WISNIEWSKI SR, THASE ME, SACHS G: History of antidepressant induced mania in the STEP 500. 2003 American Psychological Association Annual Meeting, San Francisco, CA, USA (2003).
   Google Scholar
• FAGIOLINI A, FRANK E, CHERRY CR et al.: Clinical indicators for the use of antidepressants in the treatment of bipolar I depression. Bipolar Disord. (2002) 4:277–282.
   PubMed Web of Science ®Google Scholar
• VIETA E, MARTINEZ-ARAN A, GOIKOLEA JM et al.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry (2002) 63:508–512.
   PubMed Web of Science ®Google Scholar
• KUPKA RW, NOLEN WA, ALTSHULER LL et al.: The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments. Br: J. Psychiatry Suppl. (2001) 41:S177–S183.
   Google Scholar
• POST RM, ALTSHULER LL, FRYE MA et al.: Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord. (2001) 3:259–265.
   PubMed Web of Science ®Google Scholar
• SCHAFFER A, MAMDANI M, LEVITT A, HERRMANN N: Effect of antidepressant use on admissions to hospital among elderly bipolar patients. Bipolar Disord. (2003) 5:81.
   Google Scholar
• ALTSHULER LL, SUPPES T, BLACK D et al.: Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry (2003) 160:1252–1262.
   PubMed Web of Science ®Google Scholar
• BAUER M, RASGON N, GROF P et al.: Relation of antidepressant to mood patterns in patients with bipolar disorder. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• STOLL AL, SEVERUS WE, FREEMAN MP et al.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1999) 56:407–412.
   PubMed Web of Science ®Google Scholar
• MISCHOULON D: Fishing for efficacy: the omega-3 story. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• SAGDUYU K: Omega-3 fatty acids to decrease irritable mood? 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• KECK PE, MCELROY SL, FREEMAN MP et al.: Randomized, placebo controlled trial of eicopentanoic acid in rapid cycling bipolar disorder. Bipolar Disord. (2003) 5:58.
   PubMedGoogle Scholar
• KECK PE, MCELROY SL, FREEMAN MP et al.: Randomized, placebo controlled trial of eicosapentanoic acid in bipolar depression. Bipolar Disord. (2003) 5:58.
   PubMedGoogle Scholar
• GRUNZE H, KASPER S, GOODWIN G et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. Workli Biol. Psychiatry (2002) 3:115–124.
   Google Scholar
• KALIN NH: Management of the depressive component of bipolar disorder. Depress. Anxiety (1996) 4:190–198.
   PubMedGoogle Scholar
• MUKHERJEE S, SACKEIM HA, SCHNUR DB: Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am. J. Psychiatry (1994) 151:169–176.
   PubMed Web of Science ®Google Scholar
• VANELLE JM, LOO H, GALINOWSKI A et al.: Maintenance ECT in intractable manic-depressive disorders. Con vuls. Ther. (1994) 10:195–205.
   PubMedGoogle Scholar
• RABHERU K, PERSAD E: A review of continuation and maintenance electroconvulsive therapy. Can. J. Psychiatry (1997) 42:476–484.
   PubMed Web of Science ®Google Scholar
• LOO C, MITCHELL P, SACHDEV P et al.: Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am. .1. Psychiatry(1999) 156:946–948.
   Google Scholar
• KLEIN E, KREININ I, CHISTYAKOV A et al.: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch. Gen. Psychiatry (1999) 56:315–320.
   PubMed Web of Science ®Google Scholar
• GRISARU N, CHUDAKOV B, YAROSLAVSKY Y, BELMAKER RH: Transcranial magnetic stimulation in mania: a controlled study. Am. J. Psychiatry(1998) 155:1608–1610.
   PubMed Web of Science ®Google Scholar
• NAHAS Z, KOZEL FA, LI X, ANDERSON B, GEORGE MS: Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord. (2003) 5:40–47.
   PubMed Web of Science ®Google Scholar
• SCARNA A, GIJSMAN HJ, MCTAVISH SF et al.: Effects of a branched-chain amino acid drink in mania. Br J. Psychiatry (2003) 182:210–213.
   PubMed Web of Science ®Google Scholar
• RUSH AJ, GEORGE MS, SACKEIM HA et al.: Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol. Psychiatry (2000) 47:276–286.
   PubMed Web of Science ®Google Scholar
• BEBCHUK JM, ARFKEN CL, DOLAN-MANJI S et al.: A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry (2000) 57:95–97.
   PubMed Web of Science ®Google Scholar
• ALTSHULER LL, FRYE MA, GITLIN MJ: Acceleration and augmentation strategies for treating bipolar depression. Biol. Psychiatry(2003) 53:691–700.
   PubMed Web of Science ®Google Scholar
• BAUER M: Thyroid hormone augmentation with levothyroxine in bipolar depression. Bipolar Disord. (2002) 4\(Suppl. 1):109–110.
   Google Scholar
• KAPLAN BJ, SIMPSON JS, FERRE RC et al.: Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. I Clin. Psychiatry (2001) 62:936–944.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, RAYMOND W, LAMB MD, DANTE DC: Quality of life in patients with bipolar disorder: does group psychoeducation have an impact? 2003 American Psychological Association Annual Meeting, San Francisco, CA, USA (2003).
   Google Scholar
• SCOTT J, GARLAND A, MOORHEAD S: A pilot study of cognitive therapy in bipolar disorders. Psycho]. Med. (2001) 31:459–467.
   PubMed Web of Science ®Google Scholar
• LAM DH, WATKINS ER, HAYWARD P et al.: A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch. Gen. Psychiatry(2003) 60:145–152.
   PubMed Web of Science ®Google Scholar
• •This is an important trial that demonstrates the usefulness of adjunctive treatment with cognitive therapy for relapse prevention in bipolar disorder.
   Google Scholar
• COLOM F, VIETA E, MARTINEZ-ARAN A et al: A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch. Gen. Psychiatry(2003) 60:402–407.
   PubMed Web of Science ®Google Scholar
• •This is an important trial that demonstrates the usefulness of adjunctive treatment with group psychoeducation for relapse prevention in bipolar disorder.
   Google Scholar
• SOLOMON DA, MILLER IW, RYAN CE, KEITNER GI, KELLEY J: Adjunctive family therapy and recovery from bipolar I mood episodes. 43rd Annual NCDEU Conference, Boca Raton, FL, USA (2003).
   Google Scholar
• PATELIS-SIOTIS I: Cognitive-behavioral therapy: applications for the management of bipolar disorder. Bipolar Disord. (2001) 3:1–10.
   PubMed Web of Science ®Google Scholar
• PERRY A, TARRIER N, MORRISS R, MCCARTHY E, LIMB K: Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br. Med. J. (1999) 318:149–153.
   PubMed Web of Science ®Google Scholar
• SCOTT J: What is the role for psychotherapy in bipolar disorders? Bipolar Disord. (2003) 5:16–17.
   Google Scholar